Previous 10 | Next 10 |
GB-102 1mg has shown competitive durability and anatomical control versus aflibercept Trend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patients Developing enhanced formulations and seeking partner funding for additional clinical ...
REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced it will host a conference call a...
Shares of Graybug Vision Inc. (NASDAQ:GRAY) traded at a new 52-week low today of $4.46. So far today approximately 488,000 shares have been exchanged, as compared to an average 30-day volume of 986,000 shares. Graybug Vision Inc. (NASDAQ:GRAY) has potential upside of 0.3% based on a curr...
Shares of Graybug Vision Inc. (NASDAQ:GRAY) traded at a new 52-week low today of $4.66. So far today approximately 488,000 shares have been exchanged, as compared to an average 30-day volume of 986,000 shares. Over the past year, Graybug Vision Inc. has traded in a range of $4.66 to $37....
Shares of Graybug Vision Inc. (NASDAQ:GRAY) traded at a new 52-week low today of $4.69. This new low was reached on below average trading volume as 488,000 shares traded hands, while the average 30-day volume is approximately 986,000 shares. In the past 52 weeks, shares of Graybug Vision...
Shares of Graybug Vision Inc. (NASDAQ:GRAY) traded today at $4.71, breaking its 52-week low. Approximately 488,000 shares have changed hands today, as compared to an average 30-day volume of 986,000 shares. In the past 52 weeks, Graybug Vision Inc. share prices are bracketed by a current...
Graybug Vision Inc. (NASDAQ:GRAY) traded at a new 52-week low today of $4.47. This new low was reached on below average trading volume as 488,000 shares traded hands, while the average 30-day volume is approximately 986,000 shares. Graybug Vision Inc is a clinical-stage biopharmaceutical...
The clinical-stage clinical-stage biopharma Graybug Vision ([[GRAY]] -14.3%) and precision oncology company PMV Pharmaceuticals ([[PMVP]] -14.2%) have lost double-digit percentage points so far as their lock-up agreements expire.Both companies went public in September 2020. Since then PMV Pha...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. A round of late-afternoon buying boosted the Dow Jones average to another record high on Friday as rising optimism around the global economic...
Wedbush analyst Liana Moussatos has downgraded shares of Grayburg Vision (GRAY) from outperform to neutral.She also cut her price target to $8 from $41.Moussatos writes that she is "perplexed" at secondary endpoint results from top-line data on the company's lead candidate, GB-102, for wet ag...
News, Short Squeeze, Breakout and More Instantly...
Graybug Vision Inc. Company Name:
GRAY Stock Symbol:
NASDAQ Market:
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 - Phase 2b results ...
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its tradin...
Toronto, Ontario--(Newsfile Corp. - March 2, 2023) - Graycliff Exploration Limited (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) (the " Company " or " Graycliff ") is pleased to announce that it has acquired the Lunge Project ("Lunge") located on the prolific Canadian Shield in the Sudbury Basin...